Effect of Interleukin-34 on Secretion of Angiogenesis Cytokines by Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis

References

• Ashraf S, Mapp PI, Walsh DA. (2010). Angiogenesis and the persistence of inflammation in a rat model of proliferative synovitis. Arthritis Rheum, 62, 1890–1898. doi:10.1002/art.27462.
   PubMedGoogle Scholar
• Brouwer E, Gouw AS, Posthumus MD, et al. (2009). Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol, 27, 945–951.
   PubMed Web of Science ®Google Scholar
• Chemel M, Le Goff B, Brion R, et al. (2012). Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis, 71, 150–154. doi:10.1136/annrheumdis-2011-200096.
   PubMed Web of Science ®Google Scholar
• Cho ML, Jung YO, Moon YM, et al. (2006). Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 103, 159–166. doi:10.1016/j.imlet.2005.10.020.
   PubMed Web of Science ®Google Scholar
• Elshabrawy HA, Chen Z, Volin MV, et al. (2015). The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis, 18, 433–448. doi:10.1007/s10456-015-9477-2.
   PubMed Web of Science ®Google Scholar
• Honorati MC, Neri S, Cattini L, Facchini A. (2006). Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage, 14, 345–352. doi:10.1016/j.joca.2005.10.004.
   PubMed Web of Science ®Google Scholar
• Hu F, Mu R, Zhu J, et al. (2014). Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis, 73, 928–936. doi:10.1136/annrheumdis-2012-202444.
   PubMed Web of Science ®Google Scholar
• Hu F, Shi L, Mu R, et al. (2013). Hypoxia-inducible factor-1α and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis. PLoS One, 8, e72650. doi:10.1371/journal.pone.0072650.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Choi B, Kang SS, et al. (2012). Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther, 14, R14. doi:10.1186/ar3693.
   PubMed Web of Science ®Google Scholar
• Kayakabe K, Kuroiwa T, Sakurai N, et al. (2012). Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis. Rheumatology, 51, 1571–1579. doi:10.1093/rheumatology/kes093.
   PubMed Web of Science ®Google Scholar
• Lee SS, Joo YS, Kim WU, et al. (2001). Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol, 19, 321–324.
   PubMed Web of Science ®Google Scholar
• Leibovich SJ, Polverini PJ, Shepard HM, et al. (1987). Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature, 329, 630–632. doi:10.1038/329630a0.
   PubMed Web of Science ®Google Scholar
• Lin H, Lee E, Hestir K, et al. (2008). Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science, 320, 807–811. doi:10.1126/science.1154370.
   PubMed Web of Science ®Google Scholar
• Marrelli A, Cipriani P, Liakouli V, et al. (2011). Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev, 10, 595–598. doi:10.1016/j.autrev.2011.04.020.
   PubMed Web of Science ®Google Scholar
• Nakahara H, Song J, Sugimoto M, et al. (2003). Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum, 48, 1521–1529. doi:10.1002/art.11143.
   PubMed Web of Science ®Google Scholar
• Neogi T, Aletaha D, AJ S, et al., American College of Rheumatology; European League Against Rheumatism. (2010). The 2010 American college of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. Arthritis Rheum, 62, 2582–2591. doi:10.1002/art.27580.
   PubMed Web of Science ®Google Scholar
• Pickens SR, Volin MV, Mandelin 2nd AM, et al. (2010). IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol, 184, 3233–3241. doi:10.4049/jimmunol.0903271.
   PubMed Web of Science ®Google Scholar
• Ryu S, Lee JH, Kim SI. (2006). IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol, 25, 16–20. doi:10.1007/s10067-005-1081-1.
   PubMed Web of Science ®Google Scholar
• Ségaliny AI, Mohamadi A, Dizier B, et al. (2015). Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer, 137, 73–85. doi:10.1002/ijc.29376.
   PubMed Web of Science ®Google Scholar
• Tian Y, Shen H, Xia L, Lu J. (2013). Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production. J Interferon Cytokine Res, 33, 398–401. doi:10.1089/jir.2012.0122.
   PubMed Web of Science ®Google Scholar
• Wang B, Ma Z, Wang M, et al. (2017). IL-34 upregulated Th17 production through increased il-6 expression by rheumatoid fibroblast-like synoviocytes. Mediators Inflamm, 2017, 1567120. doi:10.1155/2017/1567120.
   PubMedGoogle Scholar
• Weber AJ, De Bandt M. (2000). Angiogenesis: general mechanisms and implications for rheumatoid arthritis. Joint Bone Spine, 67, 366–383.
   PubMed Web of Science ®Google Scholar
• Westra J, Brouwer E, Bos R, et al. (2007). Regulation of cytokine-induced HIF-1alpha expression in rheumatoid synovial fibroblasts. Ann N Y Acad Sci, 1108, 340–348. doi:10.1196/annals.1422.035.
   PubMed Web of Science ®Google Scholar
• Yamada-Ohnishi Y, Azuma H, Urushibara N, et al. (2004). Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody. Stem Cells Dev, 13, 315–322. doi:10.1089/154732804323099244.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yue Y, Cheng W, et al. (2013). Hypoxia-inducible factor: a potential therapeutic target for rheumatoid arthritis. Curr Drug Targets, 14, 700–707.
   PubMed Web of Science ®Google Scholar